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appropriate therapeutic choice: taking into 
account the embolic and hemorrhagic patient 
risk, and the risk associated with the use of 
anticoagulant therapy.
The pharmacoeconomic analyses below have 
been carried out by adapting a decision tree/
Markov model simulating the clinical expe-
rience of NVAF patients according to their 
probability of incurring an ischemic event, or 
cardiovascular disease. The first paper reports 
on a cost/effectiveness analysis of the use of 
apixaban relative to the standard of care in 
the prevention of thromboembolic events in 
vitamin K antagonist suitable and unsuitable 
patients. The second presents a budget im-
pact analysis that compares NVAF patients 
eligible for treatment with NOACs in two 
scenarios – with and without apixaban. Clini-
cal comparative effectiveness parameters 
among NOACs originate from on adjusted 
indirect comparison (Bucher’s method) using 
warfarin as common comparator.
We hope that this information will support in-
formed decisions by clinicians and especially 
payers.
The presented supplement of Farmeconomia. 
Health Economics and Therapeutic Pathways 
focuses on the economic impact associated 
with cerebrovascular events related to non-val-
vular atrial fibrillation (NVAF) from the Italian 
National Health System (NHS) perspective. 
A brief look into the scientific literature pro-
vides an overview on the burden of AF in the 
Italian population. In 2010, it was estimated 
that about one million of Italian patients are 
living with AF [1] and about 70% of them 
is affected by NVAF [2]. The prevalence of 
NVAF increases with age: much more than 
10% of NVAF patients are over 80 years. The 
number of affected patients is expected to in-
crease in the next years [2]. 
AF is associated with stroke and systemic 
embolism, and increased mortality. The cur-
rent preventive measures include Vitamin 
K antagonists and antiplatelet agents, and 
recently new oral anticoagulants (NOACs) 
joined them. NOACs are offering a new op-
tion at the disposal of physicians to better 
manage risk of stroke and systemic embolism 
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